Source access required
CVR360 has not loaded official Danish source data for this company yet. No AI or financial conclusion is generated without source-backed facts.
HA
Hemab ApS
aktivCVR 40837590AnpartsselskabNordre Fasanvej 215, 2000 FrederiksbergFremstilling af farmaceutiske præparater
- Latest accounts
- 2025
- Statement scope
- Consolidated
- Verified
- 06 Nov 2026
- Sources
- 5
What changed?
Source-backed changes, not an assessment.
1 source
Key figures
Latest period: 2025
Revenue
Not available from the published filing—
Not available from the published filing
Operating profit
Not available from the published filing—
Not available from the published filing
Net result
DKK -61.4m
Latest period
Source details
Source: dk-regnskabsdata-live-40837590-1793934135085
Document: dk-regnskabsdata-40837590-AZ8Ya9n3Y4y0EUXkwCBu-1
XBRL: d:ProfitLoss
Period: 01 Jan 2025 - 31 Dec 2025
Technical details
Context: c13
Unit: u8
Equity
DKK 183.4m
Equity ratio: 93.9%
Source details
Source: dk-regnskabsdata-live-40837590-1793934135085
Document: dk-regnskabsdata-40837590-AZ8Ya9n3Y4y0EUXkwCBu-1
XBRL: d:Equity
Period: 01 Jan 2025 - 31 Dec 2025
Technical details
Context: c2320
Unit: u8
Development
Reported values. Missing periods appear as gaps.
RevenueNet result
Tabular view of development
| Year | Revenue | Net result |
|---|---|---|
| 2022 | — | DKK -21.2m |
| 2023 | — | DKK -22.6m |
| 2024 | — | DKK -48.2m |
| 2025 | — | DKK -61.4m |